中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
7期
32-33
,共2页
盐酸非索非那定片%丙酸氟替卡松%变应性鼻炎%临床疗效%免疫水平
鹽痠非索非那定片%丙痠氟替卡鬆%變應性鼻炎%臨床療效%免疫水平
염산비색비나정편%병산불체잡송%변응성비염%림상료효%면역수평
Fexofenadine Hydrochloride Tablets%fluticasone propionate%allergic rhinitis%clinical efficacy%immune level
目的：探讨盐酸非索非那定片联合丙酸氟替卡松对变应性鼻炎的疗效及血清干扰素－γ(IFN －γ)及白细胞介素(IL －4)的影响。方法将86例变应性鼻炎患者随机分成观察组和对照组，各43例。对照组给予丙酸氟替卡松鼻喷剂喷鼻治疗，观察组加用口服盐酸非索非那定片治疗，观察两组患者临床症状积分、临床疗效、治疗前后血清 IFN －γ 及 IL －4 的变化，以及不良反应。结果观察组临床症状评分为（3.84±1.65）分，明显低于对照组( P ﹤0.01)；观察组治疗总有效率为90.70%，明显高于对照组的72.09%( P ﹤0.05)；观察组治疗后 IFN －γ 为（56.14±10.34）ng / mL，明显低于对照组的(78.32±12.62）ng / mL( P ﹤0.01)，而 IL －4 为（68.61±10.26）ng / mL，明显高于对照组的(57.40±11.83）ng / mL( P ﹤0.01)；两组不良反应比较无统计学差异( P ﹥0.05)。结论盐酸非索非那定片、丙酸氟替卡松联合用药方案治疗变应性鼻炎，能有效改善临床症状，改善免疫失衡状态，提高治疗效果。
目的：探討鹽痠非索非那定片聯閤丙痠氟替卡鬆對變應性鼻炎的療效及血清榦擾素－γ(IFN －γ)及白細胞介素(IL －4)的影響。方法將86例變應性鼻炎患者隨機分成觀察組和對照組，各43例。對照組給予丙痠氟替卡鬆鼻噴劑噴鼻治療，觀察組加用口服鹽痠非索非那定片治療，觀察兩組患者臨床癥狀積分、臨床療效、治療前後血清 IFN －γ 及 IL －4 的變化，以及不良反應。結果觀察組臨床癥狀評分為（3.84±1.65）分，明顯低于對照組( P ﹤0.01)；觀察組治療總有效率為90.70%，明顯高于對照組的72.09%( P ﹤0.05)；觀察組治療後 IFN －γ 為（56.14±10.34）ng / mL，明顯低于對照組的(78.32±12.62）ng / mL( P ﹤0.01)，而 IL －4 為（68.61±10.26）ng / mL，明顯高于對照組的(57.40±11.83）ng / mL( P ﹤0.01)；兩組不良反應比較無統計學差異( P ﹥0.05)。結論鹽痠非索非那定片、丙痠氟替卡鬆聯閤用藥方案治療變應性鼻炎，能有效改善臨床癥狀，改善免疫失衡狀態，提高治療效果。
목적：탐토염산비색비나정편연합병산불체잡송대변응성비염적료효급혈청간우소－γ(IFN －γ)급백세포개소(IL －4)적영향。방법장86례변응성비염환자수궤분성관찰조화대조조，각43례。대조조급여병산불체잡송비분제분비치료，관찰조가용구복염산비색비나정편치료，관찰량조환자림상증상적분、림상료효、치료전후혈청 IFN －γ 급 IL －4 적변화，이급불량반응。결과관찰조림상증상평분위（3.84±1.65）분，명현저우대조조( P ﹤0.01)；관찰조치료총유효솔위90.70%，명현고우대조조적72.09%( P ﹤0.05)；관찰조치료후 IFN －γ 위（56.14±10.34）ng / mL，명현저우대조조적(78.32±12.62）ng / mL( P ﹤0.01)，이 IL －4 위（68.61±10.26）ng / mL，명현고우대조조적(57.40±11.83）ng / mL( P ﹤0.01)；량조불량반응비교무통계학차이( P ﹥0.05)。결론염산비색비나정편、병산불체잡송연합용약방안치료변응성비염，능유효개선림상증상，개선면역실형상태，제고치료효과。
Objective To study the effect of Fexofenadine Hydrochloride Tablets combined with fluticasone propionate on the symptoms and serum levels of IFN - γ and IL - 4 in allergic rhinitis. Methods 86 patients with allergic rhinitis were randomly divided into the observation group and the control group, 43 cases in each group. The control group was given Fluticasone Propionate Nasal Spray for conducting the nasal spray therapy, while the observation group was added with oral Fexofenadine Hydrochloride Tablets. The clinical symptoms integral, clinical efficacy, change of serum IFN - γ and IL - 4 levels before and after treatment, and adverse reactions were ob-served and compared between the two groups. Results The clinical symptom scores in the observation group were 3. 84 ± 1. 65, which were significantly lower than those in the control group; the effective rate in the observation group was 90. 70% , which was significantly higher than 72. 09% in the control group; serum IFN - γ level was (56. 14 ± 10. 34) ng / mL, which was significantly lower than (78. 32 ± 12. 62) ng / mL that in the control group( P ﹤ 0. 05), serum IL - 4 level was (68. 61 ± 10. 26) ng / mL, which was significantly higher than (57. 40 ± 11. 83) ng / mL in the control group( P ﹤ 0. 01); there were no statistical difference in the adverse reactions be-tween the two groups( P ﹥ 0. 05) . Conclusion The combination medication scheme of Fexofenadine Hydrochloride Tablets and fluticas-one propionate for treating allergic rhinitis can effectively improve the clinical symptoms, improve immune imbalance status and increase the treatment effect.
